Vanguard Group
NDRM

Vanguard Group’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Vanguard Group’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-55,015
Closed -$2.14M – 4167
2017
Q3 		$2.14M Buy
55,015
+48,000
+684% +$1.77M ﹤0.01% 3376
2017
Q2 		$210K Buy
+7,015
New +$182K ﹤0.01% 3895

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Vanguard Group's NDRM Position: Q4 2017 in Review

Vanguard Group sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 55,015 shares — an estimated $2.14M sold.

Vanguard Group first reported a position in NDRM in Q2 2017 and held it in 2 quarters. The position peaked at $2.14M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Vanguard Group reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Vanguard Group sold 55,015 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $2.14M.
  • Vanguard Group first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2017 and held it in 2 quarters.
  • Vanguard Group's NeuroDerm Ltd. Ordinary Shares position peaked at $2.14M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.